Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Krækjan er vistuð á klemmuspjaldið
StaðaRáðningar
Styrktaraðilar
University of California, San Diego
Samstarfsmenn
University of Zurich, Balgrist Hospital
Spine Institute of San Diego (Spine Zone)

Lykilorð

Útdráttur

Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition experience suboptimal or poor outcomes. These patients demonstrate disability and deficits in functional capacity, including strength and endurance of the lumbar musculature. Muscle-specific changes in individuals with LBP include altered muscle volume, fatty infiltration and fibrosis, and fiber area and type. Importantly, these changes are insensitive to rehabilitation in patients with continued chronic or recurrent symptoms. While normal disuse-related atrophy in the presence of LBP is expected, more severe or chronic pathology, such as inflammation and fiber damage, may be inducing irreversible fiber degeneration and fatty/fibrotic tissue changes that impair muscle function and recovery. While the structural and adaptive capacities of healthy muscle are well understood, muscle recovery in the presence of pathology is less clear. To address this gap in knowledge, the purpose of this project is to compare structural, physiological, and adaptive responses of muscle in the presence of acute and chronic lumbar spine pathology. The central hypothesis is that chronic injury results in a state of muscle inflammation, atrophy, fibrosis, and muscle degeneration that is not responsive to exercise. The Investigators will identify which patients respond to exercise by examining muscle hypertrophic, fibrotic, inflammatory, and adipogenic gene expression profiles. Patients will be followed for six months post-operatively to measure muscle recovery and strength.

Lýsing

AIM: To determine the effect of exercise on induction of muscle hypertrophic, fibrotic, inflammatory, and adipogenic pathways in patients with mild versus severe fatty infiltration of the multifidus muscle. Rationale. The objectives of this aim are to 1) measure molecular responses of muscle to a well-defined bout of pre-operative exercise, and 2) to determine if baseline morphological or exercise-induced molecular responses predict muscle structural recovery and functional gains up to 6 months post-operatively.

Design. This will be a longitudinal study of 40 patients with mild (< 20%) versus severe (> 50%) fatty infiltration. Non-exercise controls will also be important and the investigators intend to use a portion of biopsied tissue from other experiments as additional controls. Prior to surgery, patients will undergo clinical and MRI examinations. Additionally, patients will undergo an exercise bout 6 hours pre-operatively, and then immediately undergo a short MRI imaging protocol to measure exercise-induced perfusion changes (IVIM). Six hours after the exercise bout, the investigators will collect biopsies of the multifidus during surgery to characterize the hypertrophic, fibrotic, adipogenic, and inflammatory responses. For primary analyses, patient groups will be selected on the basis of severity of muscle fatty infiltration. Group ages and genders will be matched because the investigators know that baseline and exercise-induced gene expression varies with age. Surgical procedure and manipulation of the disc intraoperatively will be documented to account for the potential for disc and other surgery-specific effects on muscle structure. Six months post-operatively, repeated measures of muscle structure will be made via MRI. At 6, 12, and 24 weeks, strength (isokinetic dynamometer) and patient-specific function (questionnaire data) will be obtained as per standard protocol.

Methods:

Physical Examination: A physical therapist with spine injury experience will conduct the clinical exam. Age, gender and body mass index (BMI), duration of symptoms, anti-inflammatory drug use, active and passive range of motion, provocative neural tension tests (measuring joint range of motion [ROM]), strength and endurance as measured on an isokinetic dynamometer (MedX Holdings Inc.), neurovascular status, Oswestry Disability Index (81), Baecke Physical Activity Questionnaire (BPA), Fear Avoidance Beliefs Questionnaire (FABQ), and Pain Catastrophizing Scale (PCS) are important measures that capture both physical and psychosocial factors known to be related to LBP and will be collected at the clinical site. This screen will be used to confirm that discogenic symptoms are isolated to levels below L4, which allows us to use vastus lateralis as an internal control muscle biopsy.

Clinical MRI: Standard axial, sagittal oblique, and coronal oblique MR images of the spine will be collected on all patients who are scheduled for surgery. To identify disc injury severity (Pfirrmann grade), muscle fatty infiltration (Kjaer grade), and to confirm injury location, T1 and T2 non-fat suppressed or contrast-enhanced axial and sagittal MR images of the spine joint will be used.

Multimodal MRI: Imaging will be performed in a single session on a state-of-the-art 3T MRI system (GE MR750). The quantity and distribution of spine muscle volume, fat volume, and connective tissue volume will be performed from supine scans using high-resolution (1mm3) 3D FSPGR, IDEAL fat-water separation, and UTE pulse sequences, respectively using a 32-channel spine array coil. IVIM will be used to quantify regional muscle activation in response to an exercise bout.

Exercise protocol: Prior to surgery, patients will be subjected to a lumbar spine exercise protocol on a MedX Lumbar extension dynamometer with a pelvic restraint system allowing for isolation of lumbar spine muscles. The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension.

Diet protocol: Importantly, the patients will remain NPO (no food or water) after the exercise bout but will have a standardized diet for 24 hours prior to the exercise bout and surgery, which mitigates the effects of diet on gene expression (137, 150-152). Evening meals will be standardized (1900h: 11 kcal/kg; 60% carbohydrate [CHO], 25% fat [FAT], 15% protein [PRO]; 2200h (3 kcal/kg; 95% CHO, 2% FAT, 3% PRO) because meal composition can acutely impact gene and protein expression.

Harvesting and storage of muscle biopsy: Muscle biopsies will be harvested within 6 hours of the exercise bout at their scheduled surgery time. Subjects will be excluded from the analysis if their biopsies are not harvested within 1 hour of the prescribed time point. Biopsies will be obtained with a standard biopsy clamp at the middle and deep margins of the multifidus muscle as noted in Aim #1 and immediately placed in RNAlater (Qiagen) for subsequent qPCR analysis or frozen in liquid nitrogen for protein abundance/phosphorylation measurements.

qPCR and western blotting: Gene expression and protein abundance will be measured by, qPCR and western blotting, respectively. Briefly, real-time PCR will be performed in a Bio-Rad CFX384 using customized plates (PrimePCR, Bio-Rad). Target gene expression will be calculated relative to values from 18S ribosomal subunit, as preliminary findings demonstrate it to be more stable than glyceraldehyde-3-phosphate dehydrogenase (GAPDH; data not presented). For genes in which we find a greater than 3-fold change in expression, western blotting will be used to assess protein abundance, as previously described.

Dagsetningar

Síðast staðfest: 02/29/2020
Fyrst lagt fram: 02/08/2018
Áætluð skráning lögð fram: 02/20/2018
Fyrst sent: 02/21/2018
Síðasta uppfærsla lögð fram: 03/11/2020
Síðasta uppfærsla sett upp: 03/15/2020
Raunverulegur upphafsdagur náms: 06/30/2019
Áætlaður aðallokunardagur: 05/31/2022
Áætlaður dagsetningu rannsóknar: 05/31/2022

Ástand eða sjúkdómur

Disc Degeneration
Low Back Pain

Íhlutun / meðferð

Other: Exercise

Stig

-

Armhópar

ArmurÍhlutun / meðferð
Experimental: Exercise
A single bout of moderate intensity lumbar extensor muscle exercise.
Other: Exercise
The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
No Intervention: Non-exercise
No exercise intervention.

Hæfniskröfur

Aldur hæfur til náms 21 Years Til 21 Years
Kyn sem eru hæf til námsAll
Tekur við heilbrigðum sjálfboðaliðum
Viðmið

Inclusion Criteria:

- Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy).

- Age 21-85 years of age.

Exclusion Criteria:

- History of lumbar spine surgery.

- Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion).

- Diabetes.

- Neuromuscular diseases.

Útkoma

Aðal niðurstöður ráðstafanir

1. Change in Multifidus Muscle Fatty Infiltration [6 months]

(% fat at 6 months - % fat at baseline / % fat at baseline)

Aðgerðir vegna aukaatriða

1. Change in Oswestry Disability Index (ODI) [6 Months]

Disability Questionnaire (10 questions, % scale is sum of 10 questions/50, higher score is worse), 6 months - baseline

2. Change in Fear Avoidance Beliefs Questionnaire (FABQ) [6 months]

Fear Avoidance Behaviors (sumo 16 items, 0-64 scale, higher score is worse), 6 months- baseline

3. Change in Pain Catastrophizing Scale (PCS) [6 months]

Pain behaviors questionnaire (sum of 13 items, 0-52 scale, higher score is worse), 6 months - baseline

4. Change in Activated Muscle Volume (%) [After exercise (within 5 minutes)]

(% muscle activation after exercise - % muscle activation at baseline / % muscle activation at baseline)

5. Change in Pain (VAS) [6 months]

Visual Analog Scale (0-100 mm scale), 6 months - baseline

6. Change in Strength [6 months]

MedEx dynamometer, Back Extensor Strength (Nm), 6 months - baseline

7. MYHC3 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

Embryonic myosin heavy chain gene expression

8. MHY3 protein abundance (ug/mg) [6 hours after a single exercise bout]

Embryonic myosin heavy chain protein abundance

9. MYOG gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

Myogenin gene expression

10. MYOG protein abundance (ug/mg) [6 hours after a single exercise bout]

Myogenin protein abundance

11. PAX7 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

PAX7 gene expression

12. PAX7 gene expression (ug/mg) [6 hours after a single exercise bout]

PAX7 protein abundance

13. ANKRD2 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

ANKRD2 gene expression

14. ANKRD2 protein abundance (ug/mg) [6 hours after a single exercise bout]

ANKRD2 protein abundance

15. MTOR gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

MTOR gene expression

16. MTOR protein abundance (ug/mg) [6 hours after a single exercise bout]

MTOR protein abundance

17. COL1A1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

COL1A1 gene expression

18. COL3A1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

COL3A1 gene expression

19. COL9A1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

COL9A1 gene expression

20. LOX gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

LOX gene expression

21. CTGF gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

CTGF gene expression

22. TGFB1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

TGFB1 gene expression

23. MMP1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

MMP1 gene expression

24. MMP3 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

MMP3 gene expression

25. MMP9 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

MMP9 gene expression

26. CEBPA gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

CEBPA gene expression

27. FABP4 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

FABP4 gene expression

28. PPARG gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

PPARG gene expression

29. PPARD gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

PPARD gene expression

30. LEP gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

LEP gene expression

31. ADIPOQ gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

ADIPOQ gene expression

32. CASP1 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

CASP1 gene expression

33. CASP3 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

CASP3 gene expression

34. TNFa gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

TNFa gene expression

35. IL10 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

IL10 gene expression

36. IL6 gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

IL6 gene expression

37. IL1B gene expression (delta CT/delta CT) [6 hours after a single exercise bout]

IL1B gene expression

38. COL1A1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

COL1A1 Protein abundance

39. COL3A1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

COL3A1 Protein abundance

40. COL9A1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

COL9A1 Protein abundance

41. LOX Protein abundance (ug/mg) [6 hours after a single exercise bout]

LOX Protein abundance

42. CTGF Protein abundance (ug/mg) [6 hours after a single exercise bout]

CTGF Protein abundance

43. TGFB1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

TGFB1 Protein abundance

44. MMP1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

MMP1 Protein abundance

45. MMP3 Protein abundance (ug/mg) [6 hours after a single exercise bout]

MMP3 Protein abundance

46. MMP9 Protein abundance (ug/mg) [6 hours after a single exercise bout]

MMP9 Protein abundance

47. CEBPA Protein abundance (ug/mg) [6 hours after a single exercise bout]

CEBPA Protein abundance

48. FABP4 Protein abundance (ug/mg) [6 hours after a single exercise bout]

FABP4 Protein abundance

49. PPARG Protein abundance (ug/mg) [6 hours after a single exercise bout]

PPARG Protein abundance

50. PPARD Protein abundance (ug/mg) [6 hours after a single exercise bout]

PPARD Protein abundance

51. LEP Protein abundance (ug/mg) [6 hours after a single exercise bout]

LEP Protein abundance

52. ADIPOQ Protein abundance (ug/mg) [6 hours after a single exercise bout]

ADIPOQ Protein abundance

53. CASP1 Protein abundance (ug/mg) [6 hours after a single exercise bout]

CASP1 Protein abundance

54. CASP3 Protein abundance (ug/mg) [6 hours after a single exercise bout]

CASP3 Protein abundance

55. TNFa Protein abundance (ug/mg) [6 hours after a single exercise bout]

TNFa Protein abundance

56. IL10 Protein abundance (ug/mg) [6 hours after a single exercise bout]

IL10 Protein abundance

57. IL6 Protein abundance (ug/mg) [6 hours after a single exercise bout]

IL6 Protein abundance

58. IL1B Protein abundance (ug/mg) [6 hours after a single exercise bout]

IL1B Protein abundance

59. Change in Multifidus muscle volume (%) [baseline]

Multifidus muscle volume (cc), (6 months - baseline/baseline)

Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge